300122 智飛生物
按盤價 
19.240 +0.030 (+0.156%)
19.240 +0.030 (+0.156%) | 2025/09 - 九個月 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | -4.011 | 6.476 | 28.954 | 35.991 | 78.813 |
| 總資產報酬率 ROA (%) | -2.471 | 3.978 | 18.292 | 22.157 | 45.108 |
| 投入資產回報率 ROIC (%) | -2.753 | 5.126 | 26.478 | 33.585 | 68.572 | 邊際利潤分析 |
| 銷售毛利率 (%) | 23.775 | 27.381 | 26.916 | 33.631 | 49.036 |
| 營業利潤率 (%) | -19.824 | 8.684 | 17.713 | 22.889 | 39.149 |
| 息稅前利潤/營業總收入 (%) | -16.911 | 9.064 | 17.744 | 22.820 | 38.995 |
| 淨利潤/營業總收入 (%) | -15.988 | 7.743 | 15.250 | 19.703 | 33.304 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 68.348 | 127.670 | 105.150 | 105.691 | 102.136 |
| 價值變動淨收益/利潤總額(%) | 0.513 | 0.000 | 0.000 | 0.000 | -0.047 |
| 營業外收支淨額/利潤總額(%) | 0.081 | -0.449 | -0.333 | -0.463 | -0.578 | 償債能力分析 |
| 流動比率 (X) | 2.803 | 2.195 | 2.351 | 2.374 | 2.085 |
| 速動比率 (X) | 1.231 | 1.015 | 1.854 | 1.768 | 1.463 |
| 資產負債率 (%) | 36.182 | 39.865 | 37.279 | 36.227 | 41.235 |
| 帶息債務/全部投入資本 (%) | 31.878 | 29.385 | 8.070 | 6.763 | 3.289 |
| 股東權益/帶息債務 (%) | 211.480 | 237.673 | 1,127.953 | 1,360.295 | 2,894.015 |
| 股東權益/負債合計 (%) | 174.739 | 150.855 | 168.247 | 176.039 | 142.511 |
| 利息保障倍數 (X) | -5.774 | 21.612 | 198.853 | 632.817 | 547.763 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 514.817 | 299.184 | 162.158 | 157.502 | 114.461 |
| 存貨周轉天數 (天) | 986.487 | 296.888 | 79.153 | 109.195 | 124.338 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 26/12/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
